Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after resection or ablation showed a 28% improvement in ...
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all approved ...
Tecentriq Hybreza is supplied in a single-dose vial containing 1875 mg of atezolizumab and 30,000 units of hyaluronidase per 15 mL. The US Food and Drug Administration (FDA) has approved Tecentriq ...
According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback